105 related articles for article (PubMed ID: 7534858)
41. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
42. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Delory T; Papot E; Rioux C; Charpentier C; Auge-Courtoi C; Michard F; Peytavin G; Descamps D; Matheron S; Yazdanpanah Y
J Med Virol; 2016 Jul; 88(7):1204-10. PubMed ID: 26636432
[TBL] [Abstract][Full Text] [Related]
43. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
44. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
[TBL] [Abstract][Full Text] [Related]
45. Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.
Stürmer M; Staszewski S; Doerr HW; Larder B; Bloor S; Hertogs K
Antimicrob Agents Chemother; 2003 Jan; 47(1):54-61. PubMed ID: 12499169
[TBL] [Abstract][Full Text] [Related]
46. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
47. Analysis of HIV-1 reverse transcriptase gene mutations in infected children treated with zidovudine.
Orlandi P; Cancrini C; Scaccia S; Romiti ML; Livadiotti S; Gattinara GC; Angelini F; Cox S; Rossi P
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):230-7. PubMed ID: 9803964
[TBL] [Abstract][Full Text] [Related]
48. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI
J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547
[TBL] [Abstract][Full Text] [Related]
49. Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.
Olson SC; Ngo-Giang-Huong N; Beck I; Deng W; Britto P; Shapiro DE; Bumgarner RE; Mullins JI; Van Dyke RB; Jourdain G; Frenkel LM
AIDS; 2015 Jul; 29(12):1467-71. PubMed ID: 26244386
[TBL] [Abstract][Full Text] [Related]
50. An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
Boucher CA
J Int Assoc Physicians AIDS Care; 1995 Nov; 1(10):30-5. PubMed ID: 11362972
[TBL] [Abstract][Full Text] [Related]
51. Rate of development of mutation at codon 215 of HIV-1 reverse transcriptase and its predictive factors at the time of initiation of zidovudine therapy.
Leal M; Rey C; Torres Y; Relimpio F; Pino R; Lissen E; Sánchez-Quijano A; Luque F
Eur J Clin Invest; 1996 Jun; 26(6):476-80. PubMed ID: 8817161
[TBL] [Abstract][Full Text] [Related]
52. Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates.
Shafer RW; Kozal MJ; Katzenstein DA; Lipil WH; Johnstone IF; Merigan TC
J Virol Methods; 1993 Mar; 41(3):297-310. PubMed ID: 8097199
[TBL] [Abstract][Full Text] [Related]
53. Reverse transcriptase mutations in HIV-1-infected children treated with zidovudine.
Unal A; Lorenzo E; Brown M; Smith L; Matsuura S; Scott G; Scott W
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Oct; 13(2):140-5. PubMed ID: 8862278
[TBL] [Abstract][Full Text] [Related]
54. Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis.
Jung M; Agut H; Candotti D; Ingrand D; Katlama C; Huraux JM
J Acquir Immune Defic Syndr (1988); 1992; 5(4):359-64. PubMed ID: 1372352
[TBL] [Abstract][Full Text] [Related]
55. Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.
Japour AJ; Chatis PA; Eigenrauch HA; Crumpacker CS
Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3092-6. PubMed ID: 1707532
[TBL] [Abstract][Full Text] [Related]
56. [Mutations of HIV-1 RT gene isolated from patients treated with AZT].
Kondo M; Saito T; Ito A; Oka S; Takata N; Imai M
Kansenshogaku Zasshi; 1993 Mar; 67(3):185-9. PubMed ID: 7683706
[TBL] [Abstract][Full Text] [Related]
57. Transient dissociation between infectious HIV-1 titer and viral RNA during the early phase of AZT treatment.
Zöllner B; Stellbrink HJ; Feucht HH; Schröter M; Baumgartner EM; Laufs R
Microbiol Immunol; 1998; 42(6):471-3. PubMed ID: 9688082
[TBL] [Abstract][Full Text] [Related]
58. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts.
Angarano G; Monno L; Appice A; Giannelli A; Romanelli C; Fico C; Pastore G
AIDS; 1994 Jul; 8(7):1013-4. PubMed ID: 7524541
[No Abstract] [Full Text] [Related]
59. Clinical correlates and molecular basis of HIV drug resistance.
Wainberg MA; Gu Z; Gao Q; Arts E; Geleziunas R; Bour S; Beaulieu R; Tsoukas C; Singer J; Montaner J
J Acquir Immune Defic Syndr (1988); 1993; 6 Suppl 1():S36-46. PubMed ID: 7678865
[TBL] [Abstract][Full Text] [Related]
60. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
Boucher CA; Lange JM; Miedema FF; Weverling GJ; Koot M; Mulder JW; Goudsmit J; Kellam P; Larder BA; Tersmette M
AIDS; 1992 Nov; 6(11):1259-64. PubMed ID: 1282015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
